Pyrotinib
- Generic Name
- Pyrotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Taizhou Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05880927
- Locations
- 🇨🇳
Taizhou Hospital, Taizhou, Zhejiang, China
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 876
- Registration Number
- NCT05841381
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-04-28
- Target Recruit Count
- 188
- Registration Number
- NCT05834764
- Locations
- 🇨🇳
JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-09-14
- Target Recruit Count
- 30
- Registration Number
- NCT05823623
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 30
- Registration Number
- NCT05806671
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT05769010
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-27
- Target Recruit Count
- 100
- Registration Number
- NCT05764941
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05751018
- Locations
- 🇨🇳
Peking Union Medical College, Beijing, Beijing, China
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05745740
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 236
- Registration Number
- NCT05638594
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.